Vraylar is a medication used to treat mental disorders such as bipolar disorder and schizophrenia. It is a once-daily oral medication that works by targeting certain receptors in the brain to help regulate mood and behavior. Vraylar is a relatively new drug, having been approved by the FDA in 2015. It is classified as an atypical antipsychotic and is used to treat both manic and depressive episodes associated with bipolar disorder. It is also used to treat schizophrenia, as well as symptoms of irritability, aggression, and mood swings associated with autism spectrum disorder. Vraylar is marketed by Allergan, a subsidiary of AbbVie, and is available in both generic and brand-name forms. Other companies in the market include Sunovion Pharmaceuticals, Otsuka Pharmaceuticals, and Intra-Cellular Therapies. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
